MARKET

DAWN

DAWN

Day One Biopharmaceuticals, Inc.
NASDAQ
8.34
+0.03
+0.36%
Closed 18:09 12/04 EST
OPEN
8.49
PREV CLOSE
8.31
HIGH
8.60
LOW
8.21
VOLUME
2.07M
TURNOVER
0
52 WEEK HIGH
14.46
52 WEEK LOW
5.64
MARKET CAP
856.31M
P/E (TTM)
-5.6466
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DAWN last week (1124-1128)?
Weekly Report · 4d ago
Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial
TipRanks · 11/25 00:25
Day One Biopharm Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 11/24 17:39
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $25 Price Target
Benzinga · 11/24 17:29
Day One Biopharmaceuticals Reveals Promising Phase 2 Trial Results
TipRanks · 11/24 17:00
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential
TipRanks · 11/24 16:45
Day One Biopharm Price Target Maintained With a $16.00/Share by Needham
Dow Jones · 11/24 14:59
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $16 Price Target
Benzinga · 11/24 14:48
More
About DAWN
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.

Webull offers Day One Biopharmaceuticals Inc stock information, including NASDAQ: DAWN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DAWN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DAWN stock methods without spending real money on the virtual paper trading platform.